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bstract
Bioactive phytochemicals are a rich source of chemopreventive substances. The bioactive constituents of Naravelia  zeylanica
L.) DC were extracted and isolated from the leaves, and two sterol compounds, taraxerol and -sitosterol, were characterized
pectroscopically. The compounds were screened for inhibition of glycogen synthase kinase-3  (GSK-3) protein, a wound-
ealing biomarker, by molecular docking and dynamic studies. Taraxerol may be a potent inhibitor of GSK-3 because it exhibited
inimum binding (−12.59 kJ mol−1) and docking (−11.25 kJ mol−1) energy. Molecular dynamics studies revealed that taraxerol
ad minimum potential energy with the target protein. Wound-healing was studied in experimental rats in  vivo. Taraxerol was
fficient, with a mean time of epithelialization of 18.28 ±  1.17 days in the excision wound model. In the incision wound model, it
ad significant activity, with a skin-breaking strength of 562.36 ±  7.60. The hydroxyproline content of granulation tissue was found
o be 1455.93 ±  0.60. Taraxerol was confirmed to have potent wound-healing activity in  silico  and in  vivo.
 2014 Taibah University. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
ing; Mohttp://creativecommons.org/licenses/by-nc-nd/3.0/).
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1.  Introduction
Naravelia  zeylanica  (L.) DC, a woody climber, is
used in the treatment of pitta, helminthiasis, skin disease,
leprosy, rheumatalgia, odontalgia, colic inflammation,
wounds and ulcers [1]. The root and stem have a strong,
penetrating smell [2]. In Kerala, India, N.  zeylanica  is
used as a drug for intestinal worms, skin diseases, leprosy
and toothache [3]. An ethnomedical survey in the West-. This is an open access article under the CC BY-NC-ND license
ern Ghats region of Karnataka showed that this plant is
used traditionally to treat many diseases and infections,
although these plants are very rare in the region [4].
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The primary function of the skin is to serve as a pro-
tective barrier against the environment. Loss of integrity
of large portions of the skin as a result of injury or illness
can lead to major disability. The dermis, derived from the
mesoderm, is a relatively thick layer comprised of fibrous
connective tissue. The primary cell type is the fibroblast,
a spindle-shaped cell, which does not frequently repli-
cate but is very active in producing extracellular proteins,
primarily collagen and elastin. Collagen is secreted into
the intercellular matrix, where it undergoes maturation
(cross-linking and coiling) into strong fibres oriented to
allow elasticity while providing tensile strength. Elastin
is processed to form elastic fibres, imparting a degree
of resting tension to the skin. There is constant, low
turnover in unstressed skin, whereas turnover is at a
higher rate when chronic mechanical stress is applied
and during healing. The ground substance of the skin is
a nonfibrous bulk of glycosaminoglycan, which provides
a semifluid matrix that lubricates the cellular and fibrillar
components and through which inflammatory and other
cells migrate and nutrients diffuse.
The dermis is subdivided into a thin, superficial layer
known as the papillary dermis and a thicker, deep portion
of reticular dermis. The subdermal plexus sends vessels
upwards to form a plexus between the reticular and papil-
lary dermis. Other structures found in the dermis include
lymphatic vessels and nerve fibres. A basement mem-
brane is found at the dermo-epidermal junction, which
is a layer composed of mucopolysaccharides but also
rich in fibronectin. Cells of the basal epidermal layer are
joined to the basement membrane by hemidesmosomes,
and the basement membrane, in turn, is anchored to the
dermis by specialized fibrils.
Wound-healing is a well-ordered, well-coordinated
process that includes inflammation, matrix deposition,
cell proliferation, tissue modelling, collagenation and
epithelialization [5]. It has been shown that the Wnt/b-
catenin pathway can enhance wound-healing [6] by
inhibiting glycogen synthase kinase-3  (GSK-3) pro-
tein, an important regulatory enzyme. A variety of
medicinal plants have been studied to determine whether
they are potential sources of wound-healing drugs.
We screened the phyto-constituents taraxerol and -
sitosterol isolated from N.  zeylanica  for wound-healing
activity in the excision, incision and dead space wound
models and in  silico  on GSK-3.
2.  Materials  and  methods
2.1.  Collection  of  plant  material
Fresh leaves of N.  zeylanica  (L.) DC were collected
from the Lakkavalli Reserve Forest range in the Westerniversity for Science 9 (2015) 41–49
Ghats region of Karnataka. The taxonomic identity of the
species was authenticated by comparison with herbarium
voucher specimens deposited in the Kuvempu Uni-
versity herbarium (KUDB/Ang/278). The leaves were
washed under running tap-water, shade-dried, powdered
mechanically in a mixer grinder, sieved (No. 10/44) and
stored in an airtight container until use.
2.2.  Preparation  of  extracts
The powdered leaves were subjected to successive
solvent extractions as follows. The powder was placed
in a 1-L thimble of a Soxhlet apparatus and extracted
with petroleum ether (40–60◦) (Merck, Mumbai, India)
for 72 h in four batches of 250 g each. Before each
extraction, it was dried at room temperature. All the
extracts were filtered and concentrated in a vacuum with
rotary flash evaporator (Büchi, Flawil, Switzerland).
Leftover solvent was completely removed in a water
bath, and the extracts were dried in a desiccator. The
crude extracts obtained from each solvent were labelled
and weighed, and the percentage yield was recorded. The
crude petroleum ether extract of N.  zeylanica  was then
subjected to qualitative tests to determine the bioactive
constituents [7].
2.3.  Isolation  and  characterization  of  bioactive
constituents
The crude extract was dissolved in a small quan-
tity of petroleum ether and carefully introduced onto
an activated silica gel column. The eluting solvent was
added gradually to maintain a steady flow adjusted
to 5–6 drops/min, and 5-ml fractions were collected.
The eluted samples were tested by thin-layer chro-
matography for similar components, and the fractions
were grouped and dried separately. One fraction that
revealed two well-separated spots was recrystallized
with benzene, and a white crystalline compound pre-
cipitated out during solvent evaporation, which was
filtered under vacuum, concentrated and purified with
benzene. These compounds were labelled NZP-1 and
NZP-2 and tested qualitatively for the presence of phy-
tochemical groups. NZP-1 reacted positively to the
Salkowaski, Liebermann–Burchard and sulphur tests
for triterpenoids, and NZP-2 reacted positively to the
Salkowaski and Liebermann–Burchard tests for steroids.
The purity of the eluted fractions was monitored by thin-
layer chromatography. The yields were 0.516 g (2.58%)
and 0.216 g (1.98%), respectively.
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.4.  In  silico  studies
The crystal structure of GSK-3  (PDB ID: 1Q5K)
as retrieved from a protein data bank [8]. Molecular
ynamics studies were carried out with Discovery Stu-
io 3.5. Molecular simulation of the protein consisted of
nergy minimization in the CHARMm force field. The
ethod of minimization depends on the size of the root
ean square (RMS) gradient, with the steepest descents
sed to conjugate higher gradients [9]. The CHARMm
orce field calculation consisted of two stages: steepest
escent minimization for 20,000 cycles, RMS gradient
.1, energy changes 0.0; and conjugate gradients for
0,000 cycles, RMS gradient 0.0001, energy change 0.0.
inimization was continued until it was easier to calcu-
ate hydrogen bond lengths. The lowest energy model
as selected for further analysis and validation. The
inding site was predicted by the receptor cavity method
Eraser algorithm) [10]. The ligands were designed and
he structure analysed by Marvin sketch [11]. Ligand
ptimization was carried out with CHARMm and Merck
olecular force field by the minimization protocol in DS
.5 [12]. Various ligand conformations were generated
ased on bond energy, CHARM energy, dihedral energy,
lectrostatic energy, initial potential energy and initial
MS gradient values. Drug likeliness was evaluated with
ipinski, ADMET and TOPKAT [13–15].
Molecular docking studies were used to investigate
he binding affinities and interaction modes between
he inhibitors and the target by LeadIT [16]. The target
rotein was loaded onto the LeadIT protein prepara-
ion workspace, and the active amino acid sites in the
arget molecule were defined during target preparation.
 sphere of 10 A˚ radius was defined as an active site.
he screened compounds were loaded onto LeadIT as
he docking library, and the maximum number of frag-
entation and iterations was set to 200. The docked
igand–target complexes were analysed carefully to iden-
ify the interactions and binding affinities. The docking
core was recorded, and docking poses were saved for
eference. Sample preparation was conducted with the
ollowing parameters: minimization, steepest descent
nd conjugate gradient each with maximum steps of 500;
eating time, 50 ps; and equilibration time, 200 ps. The
imulations were produced with a total production time
f 20 ns with the canonical ensemble (in which the num-
er of particles (N) and volume (V) of the system are
eld constant, and the temperature (T) is in equilibrium
ith that of its heat bath), a temperature decay time of
.4 ps and a target temperature of 310 K. RMS devia-
ions of protein–ligand complex, the potential energy
f the protein–ligand complex and the H-bond distanceiversity for Science 9 (2015) 41–49 43
were determined in the analyse trajectory function after
molecular dynamics simulation [17].
2.5.  Pharmacological  evaluation
2.5.1.  Drug  formulations
Suspensions of the extract of the leaves of N.  zey-
lanica and its isolated constituents were dispersed in 1%
Tween 80 (stock suspension prepared by triturating 1 g in
distilled water and made up to 100 ml) to obtain a dosage
form at a concentration of 25 mg/ml for intraperitoneal
injection. For topical administration, 1% (w/w) ointment
cream bases of all test samples were prepared by the
fusion method (melting ingredients method) described
by Bharath [18]. For 1 kg of ointment cream base, 20 g
white bees’ wax, 30 g hard paraffin and 50 g cetyl alcohol
were placed in an evaporating dish, with 900 g of white
soft paraffin. The dish was placed as deeply as possible
in a water bath and stirred well during melting of the
ingredients; the contents were then decanted into a hot
dish to remove foreign matter and stirred until the oint-
ment was cool, when it was finally allowed to settle. All
the formulations were prepared freshly.
2.5.2.  Care  of  rats
Albino rats of each sex weighing 150–200 g were
housed six per polypropylene cage, fed a commercial
diet (Hindustan Lever Ltd., Bangalore) and given water
ad libitum  throughout the experiment, except for a short
fasting period before the study. The Institutional Ethical
Committee (Registration No. 144/1999/CPCSEA/SMG)
approved the study protocol.
2.5.3.  Acute  toxicity  studies  in  mice
The acute toxicity of the extracts and isolated
constituents of N.  zeylanica  was evaluated after intraperi-
toneal injection to Swiss albino mice as reported
previously [19], with some modifications. The LD50 was
evaluated in a biphasic manner. The animals were starved
of feed but allowed access to water 24 h before the study.
In as initial exploratory step (phase I), the range of
doses that had toxic effects was established by intraperi-
toneal administration of 10, 100, 1000 or 1500 mg/kg
body weight to four groups of four mice each. In phase
II, doses of 250, 300, 400 and 500 mg/kg were given
intraperitoneally to four other groups of mice. The mice
were observed for 24 h for behavioural signs such as
nervousness, excitement, dullness, ataxia or death. The
maximum nonlethal and the minimum lethal doses were
thus determined with only about 32 animals. One tenth
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of the LD50 was selected as the maximum dose for eval-
uating the pharmacological activity of the extracts.
2.6.  Wound-healing  activity
2.6.1.  Dosage
One group of animals served as controls, a second
group served as the reference standard and received 0.2%
(w/w) nitrofurazone ointment (Eskeyef, Mumbai, India),
the third group was treated with the extract, animals in
the fourth group received taraxerol, and animals in the
fifth groups were treated with -sitosterol.
2.6.2. Excision  wound
The excision wound model was used to assess the
capacity of the extract to promote the healing of trauma
wounds, assessed from the rate of wound contraction
and the number of days required for complete epithelial-
ization of the wound area. The rats were inflicted with
excision wounds as described elsewhere [20] under light
ether anaesthesia. In this model, the skin on the dorsal
thoracic region was excised to full thickness to obtain
a wound area of about 500 mm2. The ointment gel was
applied topically daily from the day of operation until
wound closure and complete epithelialization by tracing
the wounds on graph paper on days 4, 8, 12 and 16 and
thereafter on alternate days until healing was complete.
The percentage wound closure was calculated, and the
number of days required for the scab to fall with no resid-
ual of the raw wound was the period of epithelialization.
2.6.3. Incision  wound
In the incision wound model, 6-cm paravertebral inci-
sions were made through the full thickness of the skin
at least 1 cm on either side of the vertebral column [21].
The wounds were closed with interrupted sutures 1 cm
apart. The animals were caged individually. The sutures
were removed on day 8 after wounding, and the skin-
breaking strength of the wounds was measured on day
10 with a tensiometer.
2.6.4. Dead  space  wound
Dead space wounds were created by subcuta-
neous implantation of sterilized cylindrical grass piths
(2.5 cm ×  0.3 cm), one on either side of the dorsal par-
avertebral surface under light ether anaesthesia [22].
The granulation tissue formed around the glass pith
was excised on day 10 after wounding, and the break-
ing strength was measured. Granulation tissues were
harvested at the same time for histological study and
colorimetric estimation of the hydroxyproline content.iversity for Science 9 (2015) 41–49
2.7.  Histopathology
The granulation tissues formed on the glass piths were
removed, fixed in 10% neutral formalin solution for 24 h,
dehydrated with a sequence of ethanol–xylene solutions
[23] and embedded in paraffin at 40–60 ◦C. Microtome
sections were taken of 10 m thicknesses. The processed
sections were stained with haematoxylin–eosin and
observed under a microscope.
3.  Results  and  discussion
3.1.  Qualitative  phytochemical  analysis
The petroleum ether extract of leaves contained no
flavanoids, but sterols, glycosides, terpenes, tannins and
quinones were found.
3.2.  Isolation  of  constituents  from  the  extract  of  N.
zeylanica leaves
Triterpenoid (NZP-1) and sterol (NZP-2) compounds
isolated from the extract gave positive colour tests
for vanillin-sulphuric acid and in the Salkowaski test
and Liebermann–Burchard reaction, indicating the pres-
ence of triterpenoids and sterols. Infrared, 1H nuclear
magnetic resonance and mass spectroscopic studies
confirmed the structures of the compounds and their
molecular formulae [24].
3.3.  In  silico  analysis
GSK-3  had three domains, a crystallographic
resolution of 2.00 A˚ and a molecular mass of
17153.2 Da. The initial and final potential energy cal-
culated by energy minimization were 10801661.13 and
−21233.81 kcal/mol, respectively. With the receptor
cavity method, 27 amino acids were found in the ligand
binding pocket: Ile62, Gly63, Val70, Tyr71, Gln72,
Ala73, Leu81, Val82, Ala83, Ile84, Lys85, Val110,
Leu132, Asp133, Tyr134, Val135, Pro136, Glu137,
Thr138, Arg141, Gln185, Asn186, Leu187, Leu188,
Leu189, Asp190 and Lys197. The structure of the active
site containing mutant and DNA binding residues is
shown in Fig. 1.
Taraxerol strongly inhibited GSK-3. The three-
dimensional and pharmacophore structure of taraxerol
is shown in Fig. 2. The isolated compounds displayed
potent inhibition of target protein. Conformity with Lip-
inski’s rule of five for the molecular properties important
for potential drugs is shown in Tables 1 and 2. Taraxe-
rol showed minimum binding of −12.59 kJ mol−1 and
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Fig. 1. Active sites on target protein. In green, binding area (mesh
surface).
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ig. 2. Three-dimensional and pharmacophore structure of taraxerol.
n pink, hydrogen donor; in blue, hydrophobic.
−1
 docking energy of −11.25 kJ mol , with acceptable
ffinity for the active pocket. Thus, taraxerol can be con-
idered a potent inhibitor of GSK-3. The protein–ligand
nteraction and the binding mode docking of taraxerol
able 1
bsorption, distribution, metabolism, excretion and toxicity (ADMET) of iso
ame Solubility Blood–brain barrier CYP2D6 Hepatotoxic
araxerol 0 4 −3.57933 −8.25473 
-Sitosterol 0 4 −1.66327 −7.13406 
logP98, logarithm of the partition coefficient between n-octanol and water.
able 2
Oxicity Prediction by Komputer Assisted Technology (TOPKAT) for isolate
ame Carcinogenicity
(male mouse)
Carcinogenicity
(female mouse)
araxerol 0.000 0.000 
-Sitosterol 0.000 0.099 Fig. 3. Protein–ligand interaction.
are presented in Fig. 3. Molecular simulations were per-
formed on the crystal structure of the docked complex
structure; the distribution of potential energy, C-alpha
RMS deviation values and hydrogen bond distance is
presented in Fig. 4.
3.4.  Wound-healing  activity  in  vivo
Wound-healing involves several phases: granulation,
wound contraction, collagenation and scar formation
[25]. Three models were used to assess the effects of
the extract and purified compounds on the concurrent
but independent stages of wound-healing. Significantly
improved wound-healing activity was observed in all
three models with all three test compounds when com-
pared with that of the reference standard nitrofurazone
and controls.
In the excision wound-healing model, there was
almost complete healing after 18.28 ±  1.17 days with
taraxerol and 19.52 ±  1.05 days with -sitosterol. In con-
trol animals, healing took up to 24 days. By day 18
lated compounds.
ity Absorption Plasma protein
binding
AlogP98 Polar surface area
3 8.59399 8.084 20.815
3 2.19303 7.097 20.815
d compounds.
Developmental
toxicity potential
Skin irritation Mutagenicity
0.000 0.000 0.000
0.053 0.000 0.000
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Fig. 4. (a) Potential energy of docked complex; (b) C-alpha root mean square deviation value of docked complex; (c) H-bond distance of docked
complex.
Table 3
Effects of isolated constituents on percentage closure of excision wound area (mm2 ± SE).
Group Day 4 Day 8 Day 12 Day 16 Mean time to epithelialization (days)
Control 25.05 ± 0.56 54.23 ± 3.14 73.03 ± 3.00 83.50 ± 1.08 24.12 ± 0.28
Nitrofurazone 43.44 ± 1.73** 76.40 ± 0.24** 86.12 ± 0.15* 98.86 ± 0.24** 17.54 ± 0.10**
Taraxerol 37.02 ± 0.68** 75.30 ± 1.13** 88.21 ± 3.11** 94.42 ± 1.36** 18.28 ± 1.17**
-Sitosterol 23.65 ± 0.96 73.40 ± 1.05** 83.72 ± 1.35 94.25 ± 1.52** 19.52 ± 1.05*
F value 20.09 13.65 6.55 29.46 12.1
Each value represents mean ± SE of four animals.
* p < 0.05 when compared with control.
** p < 0.01 when compared with control.
H. Raja Naika et al. / Journal of Taibah University for Science 9 (2015) 41–49 47
Table 4
Effect of crude extract and isolated constituents on healing of incision
wound.
Group Breaking strength (g)
Control 403.00 ± 23.22
Nitrofurazone 656.18 ± 21.95**
Petroleum ether extract of N. zeylanica 574.85 ± 2.08**
Taraxerol 562.36 ± 7.60**
-Sitosterol 556.85 ± 30.55**
F value 14.34
Each value represents mean ± SE of four animals.
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Fig. 5. (a) Histological section of granuloma tissue of control animal,
showing incomplete healing and less epithelialization. Arrows show
macrophages and less collagen formation, indicating incomplete heal-
ing (H&E, 10×); (b) histological section of granuloma tissue of animal
animals showed (Fig. 5a) less epithelialization, fibrosis,
T
E
G
C
N
P
T

F
E** p < 0.01 when compared with control.
fter wounding, epithelialization was complete in ani-
als given the standard drug nitrofurazone, with 98.86%
ound contraction (Table 3).
In the incision model, the extract significantly
ncreased the skin tensile strength by day 10
fter wounding (574.85 ±  2.08 g), as did the isolated
onstituents (taraxerol, 562.36 ±  7.60 g; -sitosterol,
56.85 ±  30.55 g). Animals treated with nitrofurazone
howed a considerable increase in the tensile strength of
he incision wound (656.18 ±  21.95 g) (Table 4).
In the dead space wound model, as in the exci-
ion and incision wound models, the extract of N.
eylanica had the highest healing capacity, as revealed
y the significantly increased dry weight of granu-
oma tissue (26.33 ±  0.25 mg), increased tissue-breaking
trength (647.00 ±  0.71 g) and increased hydroxypro-
ine content (1793.83 ±  0.64 g/100 g). Taraxerol also
ad excellent wound-healing capacity, with signif-
cantly increased dry weight of granuloma tissue
21.02 ±  0.70 mg), increased tissue-breaking strength
657.12 ±  19.12 g) and increased hydroxyproline con-
ent (1455.93 ±  0.60 g/100 g). -Sitosterol, however,
howed only moderate healing activity (Table 5).
able 5
ffect of crude extract and isolated constituents of N. zeylanica on healing of
roup Granulation tissue (mg) 
Wet weight Dry we
ontrol 80.53 ± 2.26 12.36
itrofurazone 134.78 ± 1.89** 26.73
etroleum ether extract of N. zeylanica 122.93 ± 0.67** 26.33
araxerol 88.02 ± 0.72* 21.02
-Sitosterol 104.85 ± 2.07* 20.35
 value 207.70 130.44
ach value represents mean ± SE of four animals.
* p < 0.05 when compared with control.
** p < 0.01 when compared with control.given standard nitrofurazone skin ointment, showing complete epithe-
lialization. Arrowheads indicate deposition of collagen fibres (H&E,
10×).
Histological study of the granulation tissue of controlcollagen formation and hydroxyproline content, indi-
cating incomplete wound-healing. The animals treated
 dead space wound.
Tissue-breaking
strength (g)
Hydroxyproline
content (g/100 g)
ight
 ± 0.43 354.12 ± 9.21 1358.78 ± 36.09
 ± 0.42** 697.37 ± 38.23** 2468.10 ± 0.82**
 ± 0.25** 647.00 ± 0.71** 1793.83 ± 0.64**
 ± 0.70** 657.12 ± 19.12** 1455.93 ± 0.60
 ± 0.24 590.28 ± 0.19** 1400.00 ± 40.82**
 56.75 113.95
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Fig. 6. (a) Histological section of granuloma tissue of animal treated
with taraxerol, showing moderate epithelialization and collagenation.
Arrows show retention of macrophages with moderate epithelialization
and fibrosis, and arrowhead shows collagen formation (H&E, 10×);
(b) histological section of granuloma tissue of animal treated with -
sitosterol 10 days after treatment, showing complete epithelialization
[
[
[
[
[and increased collagen deposition. Arrowhead shows increase in col-
lagen formation and completes healing with more fibroblasts (H&E,
10×).
with nitrofurazone showed increased collagenation and
decreased accumulation of macrophages at the site of
injury (Fig. 5b).
Wound-healing was significantly better in the
taraxerol-treated group, especially with regard to colla-
gen formation and number of macrophages, similar to the
reference drug nitrofurazone (Fig. 6a), while -sitosterol
was less effective (Fig. 6b).
4.  ConclusionOf the two isolated compounds, taraxerol showed
greatest inhibition of GSK-3  protein in molecu-
lar docking and dynamics studies. As it showed
[
[iversity for Science 9 (2015) 41–49
minimum binding (−12.59 kJ mol−1) and docking
(−11.25 kJ mol−1) energy with acceptable affinity
towards the active pocket, taraxerol can be considered
a good inhibitor of GSK-3. Molecular dynamics stud-
ies showed that taraxerol has minimum potential energy
with the target protein. In  vivo, taraxerol was also more
active than -sitosterol and the petroleum ether extract
of the leaves of N.  zeylanica.
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